Company Description
Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States.
The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and infant drug-resistant epilepsies; and OV4071, a first-in-human oral potassium-chloride cotransporter 2 direct activator which is in Phase 1 clinical trials for the treatment of psychosis associated with parkinson's disease, lewy body dementia, and acute schizophrenia.
It has license and collaboration agreements with AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
| Country | United States |
| Founded | 2014 |
| IPO Date | May 5, 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 23 |
| CEO | Margaret Alexander |
Contact Details
Address: Hudson Commons, 441 9th Avenue New York, New York 10001 United States | |
| Phone | 646 661 7661 |
| Website | ovidrx.com |
Stock Details
| Ticker Symbol | OVID |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001636651 |
| CUSIP Number | 690469101 |
| ISIN Number | US6904691010 |
| Employer ID | 46-5270895 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Margaret Alexander | Chief Executive Officer, President and Director |
| Dr. Jeremy Max Levin Ba Zoology, Dphil, M.D., Mb Bchir, Ph.D. | Co-Founder and Executive Chairman |
| Jeffrey A. Rona | Chief Business and Financial Officer and Corporate Secretary |
| Dr. Zhong Zhong Ph.D. | Chief Scientific Officer |
| Dr. Julia Tsai Ph.D. | Senior Vice President of Clinical Development |
| Dr. Toshiya Nishi D.V.M. | Head of Epilepsy Research |
| Dr. Manal Morsy M.B.A., M.D., PH.D. | Chief Regulatory Officer |
| Victoria Fort | Senior Vice President of Corporate Affairs and Corporate Strategy |
| Charles Ross Carter | Senior Vice President of Finance and Financial Planning |
| Dr. Petra Kaufmann M.D., M.S. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 27, 2026 | ARS | Filing |
| Apr 27, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 27, 2026 | DEF 14A | Other definitive proxy statements |
| Apr 27, 2026 | 424B3 | Prospectus |
| Apr 24, 2026 | EFFECT | Notice of Effectiveness |
| Apr 21, 2026 | S-3 | Registration statement under Securities Act of 1933 |
| Apr 20, 2026 | 8-K | Current Report |
| Mar 18, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 18, 2026 | 10-K | Annual Report |
| Mar 18, 2026 | 8-K | Current Report |